Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 144

1.

High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone.

Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, Sahr F, Salata RA.

Open Forum Infect Dis. 2018 Aug 23;5(9):ofy208. doi: 10.1093/ofid/ofy208. eCollection 2018 Sep.

2.

HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic.

Yendewa GA, Poveda E, Yendewa SA, Sahr F, Quiñones-Mateu ME, Salata RA.

AIDS Rev. 2018 Apr-Jun;20(2):104-113. Review.

PMID:
29938704
3.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).

AIDS Study Group GeSIDA of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan.

Enferm Infecc Microbiol Clin. 2018 May 11. pii: S0213-005X(18)30075-2. doi: 10.1016/j.eimc.2018.02.010. [Epub ahead of print] English, Spanish.

PMID:
29759422
5.

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.

Grandal M, Pernas B, Tabernilla A, Mariño A, Álvarez H, Valcarce N, Mena A, Castro-Iglesias A, Pérez AB, Delgado M, Poveda E.

J Med Virol. 2018 Jun;90(6):1094-1098. doi: 10.1002/jmv.25048. Epub 2018 Mar 12.

PMID:
29427437
6.

Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.

Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Pernas-Souto B, Llibre JM, Poveda E.

AIDS. 2018 Jan 2;32(1):121-125. doi: 10.1097/QAD.0000000000001679.

PMID:
29112068
7.
8.

Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication.

Pernas B, Rego-Pérez I, Tabernilla A, Balboa V, Relaño S, Grandal M, Crespo M, Mena Á, Castro-Iglesias Á, Blanco FJ, Poveda E.

J Antimicrob Chemother. 2017 Nov 1;72(11):3159-3162. doi: 10.1093/jac/dkx272.

PMID:
28961892
9.

Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.

Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Martín-Herranz I, Castro-Iglesias Á, Poveda E.

Basic Clin Pharmacol Toxicol. 2017 Nov;121(5):442-446. doi: 10.1111/bcpt.12828. Epub 2017 Jul 16.

10.

Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing.

Fernández-Caballero JA, Chueca N, Poveda E, García F.

AIDS Rev. 2017 Oct-Dec;19(4):231-238. Review.

PMID:
28534892
11.

When is Early Antiretroviral Therapy Early Enough for HIV Remission?

Poveda E, Crespo M.

AIDS Rev. 2017 Apr - Jun;19(2):113-114. Review.

PMID:
28534887
12.

Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.

Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Baliñas J, Rodríguez-Martínez G, Mena Á, Poveda E.

AIDS. 2017 May 15;31(8):1099-1107. doi: 10.1097/QAD.0000000000001448.

PMID:
28441174
13.

Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.

Tabernilla A, Grandal M, Pernas B, Castro-Iglesias A, Rodríguez-Osorio I, Mena A, Delgado M, Cid P, Pedreira JD, Poveda E.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):781-785. doi: 10.1097/MEG.0000000000000882.

PMID:
28410351
14.

HTLV infection in HCV-antibody positive patients in Spain.

Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C.

AIDS Res Hum Retroviruses. 2017 Mar 7. doi: 10.1089/AID.2016.0323. [Epub ahead of print]

PMID:
28269998
15.

Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV.

Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E.

HIV Med. 2017 Oct;18(9):685-689. doi: 10.1111/hiv.12502. Epub 2017 Feb 23.

PMID:
28230318
16.

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients.

Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E.

J Clin Virol. 2017 Mar;88:58-61. doi: 10.1016/j.jcv.2017.01.003. Epub 2017 Jan 18.

PMID:
28183063
17.
18.

News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.

Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F.

AIDS Rev. 2017 Jan-Mar;19(1):47-53. Review.

PMID:
28182613
19.

Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.

Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E.

J Med Virol. 2017 Jul;89(7):1304-1308. doi: 10.1002/jmv.24766. Epub 2017 Mar 14.

PMID:
28079256
20.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R; PROTEST study group.

HIV Med. 2017 Aug;18(7):482-489. doi: 10.1111/hiv.12479. Epub 2016 Dec 30.

PMID:
28035758

Supplemental Content

Loading ...
Support Center